CD137L Antibody [41B436] | 36-030

CD137L Antibody [41B436] | 36-030 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Recombinant human CD137L extracellular domain.

Research Area: Cancer, Immunology

Tested Application: E, Flow, ICC, WB

Application: ELISA: (direct or indirect: 1:500-1:5, 000) . Flow Cytometry: (1:1, 000) . Immunocytochemistry: (see reference Nr. 2) . Western blot: (1:2, 000) . Optimal conditions should be determined individually for each application.

Specificiy: Recognizes extracellular domain of human CD137L. Does not cross-react with mouse CD137L.

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: N/A

Clonality: Monoclonal

Clone: 41B436

Isotype: IgG1, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Liquid. 0.2um-filtered solution in PBS, pH 7.4. Contains no preservatives.

Concentration: 1 mg/ml

Storage Condition: Stable for at least 1 year after receipt when stored at -20˚C.

Alternate Name: 4-1BBL; TNFSF9

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: The CD137 ligand (CD137L, 4-1BBL) is a member of the tumor necrosis factor (TNF) family. CD137L is a type II, transmembrane protein found on activated macrophages, dendritic cells and mature B cells. The interaction with its receptor 4-1BB induces recruitment of TNF receptor-associated factor 1 (TRAF1) and TRAF2 and interaction with the kinase p56lck. CD137 and CD137L have been reported to be involved in tumor rejection, apoptosis, anti-viral immunity, diabetes, in T and B cell co-stimulation and modulation of the immune response.